Welcome to LookChem.com Sign In|Join Free

CAS

  • or

780705-64-8

Post Buying Request

780705-64-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

780705-64-8 Usage

Description

1-N-Boc-4-pyriMidin-2-yl-piperazine is a chemical compound that belongs to the class of piperazines. It is a derivative of piperazine and contains a Boc (tert-butoxycarbonyl) protecting group and a pyrimidine ring. 1-N-Boc-4-pyriMidin-2-yl-piperazine is known for its potential applications in the synthesis of pharmaceuticals and agrochemicals, as well as its potential antiproliferative and antitumor activities. It has also been investigated for its potential use in the treatment of central nervous system disorders, making it a versatile compound with various potential applications in the fields of medicine and agriculture.

Uses

Used in Pharmaceutical Synthesis:
1-N-Boc-4-pyriMidin-2-yl-piperazine is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its presence can contribute to the development of new medications with improved efficacy and safety profiles.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1-N-Boc-4-pyriMidin-2-yl-piperazine is used as an intermediate in the synthesis of agrochemicals, potentially leading to the development of new pesticides or other agricultural chemicals that can enhance crop protection and yield.
Used in Antitumor Research:
1-N-Boc-4-pyriMidin-2-yl-piperazine is used as a subject of study in antitumor research due to its potential antiproliferative and antitumor activities. Scientists are investigating its ability to inhibit the growth of cancer cells, which could lead to the development of new cancer treatments.
Used in Central Nervous System Disorder Treatment:
1-N-Boc-4-pyriMidin-2-yl-piperazine is also being explored for its potential use in the treatment of central nervous system disorders. Researchers are examining its effects on neurological conditions to determine if it can be utilized in the development of new therapeutic agents for such disorders.

Check Digit Verification of cas no

The CAS Registry Mumber 780705-64-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,8,0,7,0 and 5 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 780705-64:
(8*7)+(7*8)+(6*0)+(5*7)+(4*0)+(3*5)+(2*6)+(1*4)=178
178 % 10 = 8
So 780705-64-8 is a valid CAS Registry Number.

780705-64-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 4-pyrimidin-2-ylpiperazine-1-carboxylate

1.2 Other means of identification

Product number -
Other names 1-N-Boc-4-Pyrimidin-2-yl-piperazine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:780705-64-8 SDS

780705-64-8Relevant articles and documents

ANTIVIRAL COMPOUNDS

-

Paragraph 90-92; 95-96; 143-145, (2020/11/12)

The invention is provides novel antiviral compounds, as well as derivatives thereof. The compounds of the invention are preferably formulated as pharmaceuticals. The invention provides the compounds for use in the prevention and treatment of infectious diseases, in particular viral diseases. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.

Full synthesis method of eptapirone

-

Paragraph 0089; 0126; 0127; 0128; 0136, (2018/09/12)

The invention discloses a full synthesis method of eptapirone. The full synthesis method comprises the following steps: (1) taking aminourea hydrochloride and trichloracetic aldehyde as raw materialsand carrying out a series of reaction to obtain 2-[2-(aminocarbonyl)hydrazono](CD-1); (2) synthesizing 6-azauracil(CD-2) by the 2-[2-(aminocarbonyl)hydrazono] under the action of sodium hydroxide; (3)taking the 6-azauracil and acetic anhydride to react to obtain 2-acetyl-2H-[1,2,4]triazine-3,5(2H,4H)-diketone(CD3); (4) taking the 2-acetyl-2H-[1,2,4]triazine-3,5(2H,4H)-diketone to react to obtain3-methyl-6-azauracil(CD-4); (5) taking the 3-methyl-6-azauracil to react to obtain 2-(4-chlorobutyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-diketone(CD-5); (6) taking 2-bromopyrimidine, 1-Boc-piperazine and triethylamine to react to obtain 4-(pyrimidine-2-yl)piperazine-1-tert-butyl formate(CD-6); furthermore, reacting to obtain 2-(1-piperazinyl)pyrimidine hydrochloride (1 to 1)(CD-7); (7) taking the 2-(4-chlorobutyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-diketone in step (5) to react with the 2-(1-piperazinyl)pyrimidine hydrochloride in step (6) to obtain the eptapirone(CD-8). The product disclosed by the invention is high in purity and yield and is suitable for industrialized production.

Iridium-catalyzed C-H borylation of heteroarenes: Scope, regioselectivity, application to late-stage functionalization, and mechanism

Larsen, Matthew A.,Hartwig, John F.

, p. 4287 - 4299 (2014/04/03)

A study on the iridium-catalyzed C-H borylation of heteroarenes is reported. Several heteroarenes containing multiple heteroatoms were found to be amenable to C-H borylation catalyzed by the combination of an iridium(I) precursor and tetramethylphenanthroline. The investigations of the scope of the reaction led to the development of powerful rules for predicting the regioselectivity of borylation, foremost of which is that borylation occurs distal to nitrogen atoms. One-pot functionalizations are reported of the heteroaryl boronate esters formed in situ, demonstrating the usefulness of the reported methodology for the synthesis of complex heteroaryl structures. Application of this methodology to the synthesis and late-stage functionalization of biologically active compounds is also demonstrated. Mechanistic studies show that basic heteroarenes can bind to the catalyst and alter the resting state from the olefin-bound complex observed during arene borylation to a species containing a bound heteroarene, leading to catalyst deactivation. Studies on the origins of the observed regioselectivity show that borylation occurs distal to N-H bonds due to rapid N-H borylation, creating an unfavorable steric environment for borylation adjacent to these bonds. Computational studies and mechanistic studies show that the lack of observable borylation of C-H bonds adjacent to basic nitrogen is not the result of coordination to a bulky Lewis acid prior to C-H activation, but the combination of a higher-energy pathway for the borylation of these bonds relative to other C-H bonds and the instability of the products formed from borylation adjacent to basic nitrogen.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 780705-64-8